Antipicornaviral compounds, compositions containing them, and methods for their use

Abstract

A magnetic circuit component having a plurality of claws arranged in a plurality of rows, with the base of each claw connected to a common yoke. A plurality of non-interlaced coils constituting a multi-phase winding are included, with the coils being wound around the bases of corresponding claws, and being distributed uniformly in the direction of motion.

What is claim is:  
     
         1 . At least one compound of the formula (I):  
       
         
           
           
               
               
           
         
       
       wherein 
 M is O or S;  
 R 1  is H, F, an alkyl group, OH, SH, or an O-alkyl group;  
 R 2  and R 5  are independently selected from H,  
                     or an alkyl group, wherein said alkyl group is different from                          with the proviso that at least one of R 2  or R 5  must be                          
 and wherein, when R 2  or R 5  is  
                     X is ═CH or ═CF and Y 1  is ═CH or ═CF,    or X and Y 1  together with Q′ form a three-membered ring in which Q′ is —C(R 10 )(R 11 )— or —O—, X is —CH— or —CF—, and Y 1  is —CH—, —CF—, or —C(alkyl)-, where R 10  and R 11  independently are H, a halogen, or an alkyl group, or, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group,    or X is —CH 2 —, —CF 2 —, —CHF—, or —S—, and Y 1  is —O—, —S—, —NR 12 —, —C(R 13 )(R 14 )—, —C(O)—, —C(S)—, or —C(CR 13 R 14 )—, 
 wherein R 12  is H or alkyl, and R 13  and R 14  independently are H, F, or an alkyl group, or, together with the atoms to which they are bonded, form a cycloalkyl group or a heterocycloalkyl group;  
   A 1 is C, CH, CF, S, P, Se, N, NR 15 , S(O), Se(O), P—OR 15 , or P—NR 15 R 16 , 
 wherein R 15  and R 16  independently are an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom to which they are bonded, form a heterocycloalkyl group;  
   D 1  is a moiety with a lone pair of electrons capable of forming a hydrogen bond; and    B 1  is H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR 17 , —SR 17 , —NR 17 R 18 , —NR 19 NR 17 R 18 , or —NR 17 OR 18 , 
 wherein R 17 , R 18 , and R 19  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;  
   
 and with the provisos that when D 1  is the moiety ≡N with a lone pair of electrons capable of forming a hydrogen bond, B 1  does not exist; and when A 1  is an sp 3  carbon, B 1  is not —NR 17 R 18  when D 1  is the moiety —NR 25 R 26  with a lone pair of electrons capable of forming a hydrogen bond, wherein R 25  and R 26  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;  
 and wherein D 1 —A 1 —B 1  optionally forms a nitro group where A 1  is N;  
 and further wherein, when R 2  or R 5  is  
                     X is ═CH or ═CF and Y 2  is ═C, ═CH, or ═CF,    or X and Y 2  together with Q′ form a three-membered ring in which Q′ is —C(R 10 )(R 11 )— or —O—, X is —CH— or —CF—, and Y 2  is —CH—, —CF—, or —C(alkyl)-, where R 10  and R 11 , independently are H, a halogen, or an alkyl group, or, together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group,    or X is —CH 2 —, —CF 2 —, —CHF—, or —S—, and Y 2  is —O—, —S—, —N(R′ 12 )—, —C(O)—, —C(R′ 13 )(R′ 14 )—, —C(S)—, or —C(CR′ 13 R′ 14 )—, 
 wherein R′ 12  is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR′ 13 , —NR′ 13 R′ 14 , —C(O)—R′ 13 , —SO 2 R′ 13 , or —C(S)R′ 13 , and R′ 13  and R′ 14 , independently are H, F, or an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group;  
   A 2  is C, CH, CF, S, P, Se, N, NR 15 , S(O), Se(O), P—OR 15 , or P—NR 15 R 16 , 
 wherein R 15  and R 16  independently are an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom to which they are bonded, form a heterocycloalkyl group;  
   D 2  is a moiety with a lone pair of electrons capable of forming a hydrogen bond; and    B 2  is H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR 17 , —SR 17 , —NR 17 R 18 , —NR 19 NR 17 R 18 , or —NR 17 OR 18 , 
 wherein R 17 , R 18 , and R 19  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;  
   and further wherein any combination of Y 2 , A 2 , B 2 , and D 2  optionally can form a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;    
 R 3  and R 6  are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —C(O)R 17 , —OR 17 , —SR 17 , —NR 17 R 18 , —NR 19 NR 17 R 18 , or —NR 17 OR 18 , 
 wherein R 17 , R 18 , and R 19  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;  
 
 or, R 3  and R 6 , together with the carbon atom to which they are attached, form a cycloalkyl group or a heterocycloalkyl group;  
 R 7  is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR 17 , —SR 17 , —NR 17 R 18 , —NR 19 NR 17 R 18 , or —NR 17 OR 18 , 
 wherein R 17 , R 18 , and R 19  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group;  
 
 or R 7 , together with R 3  or R 6  and the atoms to which they are attached, forms a heterocycloalkyl group;  
 R 20  is H, OH, or any suitable organic moiety; and  
 Z and Z 1  are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —C(O)R 21 , —CO 2 R 21 , —CN, —C(O)NR 21 ,R 22 , —C(O)NR 21 OR 22 , —C(S)R 21 , —C(S)NR 21 R 22 , —NO 2 , —SOR 21 , —SO 2 R 21 , —SO 2 NR 21 R 22 , —SO(NR 21 )(OR 22 ), —SONR 21 , —SO 3 R 21 , —PO(OR 21 ) 2 , —PO(R 21 )(R 22 ), —PO(NR 21 R 22 )(OR 23 ), PO(NR 21 R 22 )(NR 23 R 24 ), —C(O)NR 21 NR 22 R 23 , or —C(S)NR 21 NR 22 R 23 , 
 wherein R 21 , R 22 , R 23 , and R 24  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of R 21 , R 22 , R 23 , and R 24 , together with the atom(s) to which they are bonded, form a heterocycloalkyl group;  
 
 or Z 1 , as defined above, together with R 1 , as defined above, and the atoms to which Z 1  and R 1  are bonded, form a cycloalkyl or heterocycloalkyl group,  
 or Z and Z 1 , both as defined above, together with the atoms to which they are bonded, form a cycloalkyl or heterocycloalkyl group;  
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof;  
 and wherein said compound, or pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof, has antipicomaviral activity with an EC 50  less than or equal to 10 μM in the HI-HeLa cell culture assay.  
 
     
     
         2 . At least one compound of  claim 1 , wherein R 1  is H or F, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         3 . At least one compound of  claim 1 , wherein R 20  is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —OR 17 , —SR 17 , —NR 17 R 18 , —NR 19 NR 17 R 18 , or —NR 17 OR 18 , wherein R 17 , R 18 , and R 19  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         4 . At least one compound of  claim 3 , wherein R 20  is the alkyl group —C(R 41 )(R 42 )NR 43 R 44 , wherein: 
 R 41 , and R 42  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group; and  
 R 43  and R 44  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —NR 45 R 46 , —C(O)R 45 , —C(S)R 45 , —C(O)NR 45 R 46 , —C(S)NR 45 R 46 , —C(O)NR 45 OR 46 , —C(S)NR 45 OR 46 , —C(O)SR 45 , —C(O)OR 45 , —C(S)OR 45 , —C(S)SR 45 , —OR 45 , —SR 45 , —C(O)NR 45 NR 46 R 47 , —C(S)NR 45 NR 46 R 47 , —SOR 45 , —SO 2 R 45 , —S(O)NR 45 R 46 , —S(O)NR 45 (OR 46 ), —SO 2 NR 45 R 46 , —SO 2 NR 45 (OR 46 ), or —SO 3 R 45 , 
 wherein R 45 , R 46 , and R 47  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group,  
 
 or wherein any suitable combination of R 41 , R 42 , R 43 , and R 44  together form a cycloalkyl group or a heterocycloalkyl group;  
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         5 . At least one compound of  claim 4 , wherein at least one of R 43  or R 44  is —C(O)SR 45  or —C(O)OR 45 , or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         6 . At least one compound of  claim 5 , wherein R 45  is an alkyl group, a cycloalkyl group, an aryl group, a heterocycloalkyl group, or a heteroaryl group, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         7 . At least one compound of  claim 6 , wherein R 45  is a C 1- C 10  alkyl group or a cycloalkyl group, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         8 . At least one compound of  claim 1 , wherein at least one of R 2  or R 5  is  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         9 . At least one compound according to  claim 8 , wherein D 1  is —OR 25 , ═O, ═S, ≡N, ═NR 25 , or —NR 25 R 26 , wherein R 25  and R 26  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the nitrogen atom to which they are bonded, form a heterocycloalkyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         10 . At least one compound according to  claim 9 , wherein D 1  is ═O; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         11 . At least one compound according to  claim 8 , wherein A 1  is C, CH, S, or S(O); or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         12 . At least one compound according to  claim 11 , wherein A 1  is C; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         13 . At least one compound according to  claim 8 , wherein B 1  is NR 17 R 18 , wherein R 17  and R 18  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         14 . At least one compound according to  claim 1 , wherein at least one of R 2  or R 5    
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         15 . At least one compound according to  claim 14 , wherein D 2  is —OR 25 , ═O, ═S, ≡N, ═NR 25 , or —NR 25 R 26 , wherein R 25  and R 26  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, or, together with the atom(s) to which they are bonded, form a heterocycloalkyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         16 . At least one compound according to  claim 15 , wherein D 2  is ═O; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         17 . At least one compound according to  claim 14 , wherein A 2  is C, CH, S, or S(O); or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         18 . At least one compound according to  claim 17 , wherein A 2  is C; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         19 . At least one compound according to  claim 14 , wherein B 2  is —NR 17 R 18 , wherein R 17  and R 18  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group; or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         20 . At least one compound according to  claim 1 , wherein A 1  is C, CH, S, or S(O) or wherein A 2  is C, CH, S, or S(O); or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         21 . At least one compound according to  claim 1 , wherein Z and Z 1  are independently H, an aryl group, or a heteroaryl group, —C(O)R 21 , —CO 2 R 21 , —CN, —C(O)NR 21 ,R 22 , —C(O)NR 21 OR 22 , —C(S)R 21 , —C(S)NR 21 R 22 , —NO 2 , —SOR 21 , —SO 2 R 21 , —SO 2 NR 21 R 22 , —SO(NR 21 )(OR 22 ), —SONR 21 , —SO 3 R 21 , —C(O)NR 21 NR 22 R 23 , or —C(S)NR 21 NR 22 R 23 ; 
 wherein R 21 , R 22 , and R 23  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of R 2 , R 22 , and R 23 , together with the atom(s) to which they are bonded, form a heterocycloalkyl group;  
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         22 . At least one compound according to  claim 1 , wherein M is O.  
     
     
         23 . At least one compound having the formula X:  
       
         
           
           
               
               
           
         
       
       wherein 
 R 61 , is H, F, or an alkyl group;  
 R 62  is selected from one of the following moieties:  
                     
 wherein 
 R 35  is H, an alkyl group, an aryl group, —OR 38 , or —NR 38 R 39 , 
 wherein R 38  and R 39  independently are H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; and  
 
 R 36  is H or an alkyl group,  
 or R 35  and R 36 , together with the nitrogen atom to which they are attached, form a heterocycloalkyl group or a heteroaryl group;  
 R 37  is an alkyl group, an aryl group, or —NR 38 R 39 , wherein R 38  and R 39  are as defined above;  
 R 50  is H, an alkyl group, an aryl group, —OR 38 , —SR 39 , —NR 38 R 39 , —NR 40 NR 38 R 39 , or  
 —NR 38 OR 39 , or R 50 and R 36 , together with the atoms to which they are attached, form a heterocycloalkyl group; 
 wherein R 38  and R 39  are as defined above, and R 40  is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, or an acyl group; and  
 
 n is 0, 1, or2;  
 
 R 63  is H or an alkyl group;  
 R 64  is H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group;  
 R 65  is H or an alkyl group;  
 R 66  is H, an acyl group, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a sulfonyl group, or a heteroaryl group;  
 R 67  is H or an alkyl group; and  
 Z and Z 1  are independently H, F, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, —C(O)R 21 , —CO 2 R 21 , —CN, —C(O)NR 21 R 22 , —C(O)NR 21 OR 22 , —C(S)R 21 , —C(S)NR 21 R 22 , —NO 2 , —SOR 21 , —SO 2 R 21 , —SO 2 NR 21 R 22 , —SO(NR 21 )(OR 22 ), —SONR 21 , —SO 3 R 21 , —PO(OR 21 ) 2 , —PO(R 21 )(R 22 ), —PO(NR 21 R 22 )(OR 23 ), —PO(NR 21 R 22 )(NR 23 R 24 ), —C(O)NR 21 NR 22 R 23 , or —C(S)NR 21 NR 22 R 23 , 
 wherein R 21 , R 22 , R 23 , and R 24  are independently H, an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an acyl group, or a thioacyl group, or wherein any two of R 21 , R 22 , R 23 , and R 24 , together with the atom(s) to which they are bonded, form a heterocycloalkyl group,  
 
 or Z and Z 1 , both as defined above, together with the atoms to which they are bonded, form a heterocycloalkyl group;  
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         24 . At least one compound according to  claim 23 , wherein R 66  is the acyl group —C(O)OR 68  or the acyl group —C(O)SR 68 , wherein R 68  is an alkyl group, a cycloalkyl group, an aryl group, a heterocycloalkyl group, or a heteroaryl group, or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         25 . At least one compound according to  claim 4 , having the formula II:  
       
         
           
           
               
               
           
         
       
       wherein R 1 , R 5 , R 6 , R 7 , R 42 , R 43 , and Z are H, R 2  is CH 2 CH 2 C(O)NH 2 , and 
 R 3  is CH 2 Ph, R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is  
                     
  and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 Ph, R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 R 3  is CH 2 (p-CH 3 )Ph, R 41  is CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
 R 3  is CH 2 (p-CH 3 )Ph, R 41  is CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         26 . At least one compound according to  claim 4 , having the formula III:  
       
         
           
           
               
               
           
         
       
       wherein R 1 , R 5 , R 6 , R 7 , R 42 , R 43 , and Z are H, R 3  is CH 2 Ph, R 2  is CH 2 CH 2 C(O)NH 2 , 
 R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         27 . At least one compound of the formula (IV):  
       
         
           
           
               
               
           
         
       
       wherein: 
 R 1 , R 5 , R 6 , R 7 , and R 42  are H, R 2  is CH 2 CH 2 C(O)NH 2 , and  
 R 3  is CH 2 (p-CH 3 )Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 4  is CH 2 Ph, and R 44  is  
                     
 R 3  is CH 2 (p-F)Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 (p-F)Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 (p-CF 3 )Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44    
                     
 R 3  is CH 2 (p-CF 3 )Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44    
                     
 R 3  is CH 2 (p-CH 3 )Ph, Z and Z 1  together form  
                     
  (where * indicates the point of attachment and the carbonyl group is cis to the R 1  group), R 41  is CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 (p-F)Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH 2 Ph, and R 44  is  
                     
 R 3  is CH 2 (p-F)Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH 2 CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 (p-CH 3 )Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 (p-CH 3 )Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH 2 CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is C(CH 3 ) 3 , and R 44  is  
                     
 R 3  is CH 2 (p-CH 3 )Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44  is  
                     
 R 3  is CH 2 (p-F)Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is cyclohexyl, and R 44  is  
                     
  or  
 R 3  is CH 2 (p-F)Ph, Z is H, Z 1  is CO 2 CH 2 CH 3 , R 41  is CH(CH 3 ) 2 , and R 44  is  
                     
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         28 . A composition comprising at least one compound of formula II:  
       
         
           
           
               
               
           
         
       
       wherein R 1  , R 5 , R 6 , R 7 , R 42 , R 43 , and Z are H, R 3  is CH 2 Ph, R 2  is CH 2 CH 2 C(O)NH 2 , 
 R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof,  
 and at least one compound of formula III:  
                     
 wherein R 1  , R 5 , R 6 , R 7 , R 42 , R 43 , and Z are H, R 3  is CH 2 Ph, R 2  is CH 2 CH 2 C(O)NH 2 ,  
 R 41  is CH 2 CH(CH 3 ) 2 , Z 1  is CO 2 CH 2 CH 3 , and R 44  is  
                     
 or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
 
     
     
         29 . A pharmaceutical composition comprising: 
 (a) a therapeutically effective amount of at least one compound as defined in  claim 1  or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof; and    (b) a pharmaceutically acceptable carrier, diluent, vehicle, or excipient.    
     
     
         30 . A method of treating a mammalian disease condition mediated by picornaviral protease activity that comprises administering to a mammal in need thereof a therapeutically effective amount of at least one compound as defined in  claim 1  or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         31 . A method of inhibiting the activity of a picornaviral 3C protease that comprises contacting the picornaviral 3C protease with an effective amount of at least one compound as defined in  claim 1  or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         32 . A method of inhibiting the activity of a rhinoviral protease that comprises contacting the rhinoviral protease with an effective amount of at least one compound as defined in  claim 1  or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof.  
     
     
         33 . A compound according to  claim 1 , or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof, wherein said antipicornaviral activity is antirhinoviral activity.  
     
     
         34 . A compound according to  claim 1 , or a pharmaceutically acceptable prodrug, salt, active metabolite, or solvate thereof, wherein said antipicornaviral activity is anticoxsackieviral activity.